-
August 4, 2021 FDA Green Lights Ketamine for Treatment of ALS"This designation not only expedites our regulatory, clinical, and product development plans but also validates...
-
August 3, 2021 Mindset Pharma Files Patent for Quickest, Cheapest Method to Synthesize Psilocybin"Based on our research, we think we're able to get to psilocybin in fewer steps...
-
August 3, 2021 Australia’s First Psychedelic Research Institute Opens with $40 Million InvestmentPsychae Institute will collaborate with other clinical research organizations to develop novel psychedelic medicines and...
-
July 28, 2021 TheraPsil’s Fight to Secure Therapeutic Psilocybin Access for All CanadiansCEO Spencer Hawkswell calls current exemptions for terminally ill under Section 56 of Canada’s Controlled...
-
July 27, 2021 Psychedelic Companies HAVN Life Sciences, MINDCURE Health Reach Manufacturing MilestonesThe global supply chain of regulated psilocybin and ibogaine continues to grow as these Canadian...
-
July 26, 2021 Akome Biotech Patents Psychedelic Drug Formulation to Treat Parkinson’s DiseaseThere is currently no known cure for the disease affecting 10 million people worldwide, but...
-
July 22, 2021 Cybin Receives Conditional Approval to Trade on NYSE AmericanAnd in other psychedelic stock news, Origin Therapeutics launches to make equity investments in emerging...
-
July 21, 2021 Wake Network Partners with Lieber Institute to Develop Genetics-Based Screening System for Psychedelic TherapiesFungi bioscience company describes the project as “one of the most robust genetics research initiatives...
-
July 20, 2021 Free Ketamine Treatment Now Available for Canadian VeteransMedavie Blue Cross partners with medical research company Braxia Scientific to cover ketamine care for...
-
July 19, 2021 Third Psychedelic Stock ETF Coming Soon, Core One Labs Prepares to List on NASDAQAdvisorshares Plant Medicine ETF will be listed on the NYSE Arca under the symbol PSIL.
